New Delhi, Feb 11: Supriya Lifescience Ltd., a cGMP-compliant pharmaceutical company with a robust global presence across more than 120 countries, has announced its unaudited financial results for the third quarter of FY26. The company specializes in API manufacturing across diverse therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic products.
Key Financial Highlights – Q3 FY26 (Consolidated)
| Particulars | Q3 FY26 | Q3 FY25 | YoY Change |
|---|---|---|---|
| Revenue (Rs Cr) | 206.44 | 185.65 | 11.2% |
| EBITDA (Rs Cr) | 72.08 | 65.96 | 9.3% |
| EBITDA Margin | 34.9% | 35.5% | -0.6% |
| PAT (Rs Cr) | 49.68 | 46.78 | 6.2% |
| PAT Margin | 24.1% | 25.2% | -1.1% |
| EPS (Rs) | 6.2 | 5.8 | 6.9% |
Business Highlights – Q3 FY26
-
Revenue grew 11.2% year-on-year to Rs 206.44 crore, driven by strong demand in global markets.
-
EBITDA stood at Rs 72.08 crore with a margin of 34.9%, while PAT reached Rs 49.68 crore with a margin of 24.1%.
-
The anesthetic segment was the primary growth driver, contributing 54% of total revenues, up from 48% in 9M FY25. The vitamins segment also improved, increasing its contribution from 11% to 12%.
-
Export markets continued to perform strongly, with Europe remaining the largest market (36% of revenues), followed by Asia (32%), Latin America (24%, up from 21%), and North America (6%, up from 3%).
-
Capacity utilization improved to 76% in 9MFY26 from 70% in FY25, reflecting operational efficiency gains from the ramp-up of Module E at the Lote Parshuram facility.
-
To support future growth, the company has acquired three land parcels near existing manufacturing facilities, strengthening its long-term expansion plans.
Commenting on the results, Mr. Satish Wagh, Executive Chairman and Whole-Time Director, Supriya Lifescience Ltd., said:
“Our performance this quarter reflects consistent execution and sustained profitability, supported by steady demand across key global markets. Exports continued to be a strong contributor, accounting for approximately 82% of revenues in Q3, with Europe forming a significant share of the business mix. Capacity utilization improved to around 76% during 9MFY26, aided by the ramp-up of Module E at our Lote Parshuram facility, enhancing operational efficiency and supply reliability. As we prepare for the commercial launch of our Ambernath formulation facility in Q4 FY26 and continue to deepen our presence in regulated markets through backward integration and new product introductions, we remain confident of driving stronger growth in the coming quarters.”